NovoCure Ltd
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
NVCR$11.81-5.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows for the years ended
| Year ended December 31, | |||
|---|---|---|---|
| U.S. dollars in thousands | 2023 | 2022 | 2021 |
| Cash flows from operating activities: | |||
| Net income (loss) | $(207,043) | $(92,534) | $(58,351) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||
| Depreciation and amortization | 10,969 | 10,624 | 10,251 |
| Accrued interest | (95) | (2,216) | (94) |
| Asset write-downs and impairment of field equipment | 493 | 955 | 649 |
| Share-based compensation | 115,608 | 106,955 | 94,900 |
| Foreign currency remeasurement loss (gain) | 161 | (3,256) | 3,231 |
| Decrease (increase) in accounts receivables and prepaid expenses | 29,414 | 2,547 | 5,270 |
| Amortization of discount (premium) | (23,084) | (1,536) | 3,101 |
| Decrease (increase) in inventories | (8,919) | (4,342) | 2,483 |
| Decrease (increase) in other long-term assets | 4,072 | 7,107 | 4,519 |
| Increase (decrease) in accounts payables and accrued expenses | 14,869 | 14,257 | 27,777 |
| Increase (decrease) in other long-term liabilities | (9,781) | (7,773) | (10,980) |
| Net cash provided by (used in) operating activities | $(73,336) | $30,788 | $82,756 |
| Cash flows from investing activities: | |||
| Purchase of property, equipment and field equipment | (27,093) | (21,358) | (24,170) |
| Proceeds from maturity of short-term investments | 1,214,982 | 1,179,289 | 958,000 |
| Purchase of short-term investments | (1,003,741) | (1,297,888) | (1,078,664) |
| Net cash provided by (used in) investing activities | $184,148 | $(139,957) | $(144,834) |
| Year ended December 31, | |||
|---|---|---|---|
| U.S. dollars in thousands | 2023 | 2022 | 2021 |
| Cash flows from financing activities: | |||
| Proceeds from issuance of shares, net | $4,416 | $5,224 | $4,546 |
| Repayment of long-term debt | (10) | (28) | (26) |
| Exercise of options | 11,381 | 10,295 | 21,182 |
| Net cash provided by (used in) financing activities | $15,787 | $15,491 | $25,702 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $131 | $(97) | $(188) |
| Increase (decrease) in cash, cash equivalents and restricted cash | 126,730 | (93,775) | (36,564) |
| Cash, cash equivalents and restricted cash at the beginning of the year | 115,834 | 209,609 | 246,173 |
| Cash, cash equivalents and restricted cash at the end of the year | $242,564 | $115,834 | $209,609 |
| Supplemental cash flow activities: | |||
| Cash paid during the year for: | |||
| Income taxes paid (refunded), net | $13,665 | $5,480 | $3,110 |
| Interest paid | $6 | $41 | $101 |
| Reconciliation of cash, cash equivalents and restricted cash: | |||
| Cash and cash equivalents | $240,821 | $115,326 | $208,802 |
| Restricted cash | $1,743 | $508 | $807 |
| Total cash, cash equivalents and restricted cash | $242,564 | $115,834 | $209,609 |
| Non-cash activities: | |||
| Right-of-use assets obtained in exchange for lease liabilities | $18,063 | $12,117 | $5,387 |
| Purchase of property incurred but unpaid at period end | $1,714 | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.